Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890923 · ClinicalTrials.gov registry record · Phase 2
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
A Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis, sponsored by Tiziana Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT06890923: Recruiting Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis, sponsored by Tiziana Life Sciences.
NCT06890923 is a Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis that is actively recruiting participants, run by Tiziana Life Sciences. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06890923, a Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis, is actively recruiting participants, sponsored by Tiziana Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension study with an opportunity for dose to be escalated based on the subject's clinical status. All subjects initiate dosing in this trial at a dose of nasal foralumab 50 µg 3 days a week (Monday, Wednesday, and Friday) for 2 weeks, followed by a 1-week rest, comprising a 3-week cycle. At week 12, the dose may be escalated to 100 µg according to pre-defined dose escalation rules. Study TILS-022 is intended to ensure all participants in TILS-021, a placebo-controlled study, will be able to receive open-label nasal foralumab for 6 months. The option to extend this trial for longer than 6 months will be explored with FDA by the Sponsor.
Primary Outcome
The safety and tolerability of 50 µg/dose and 100 µg/doses of foralumab nasal as measured by adverse event reports
Conditions Studied
Interventions
- DRUG Foralumab TZLS-401 100 µg
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 2 |
What NCT06890923 shows while recruiting
NCT06890923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Non-Active Secondary Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Foralumab TZLS-401 100 µg is the first listed.
NCT06890923 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06890923 about?
NCT06890923 is a clinical study titled "Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis". Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension s...
What is the current status of trial NCT06890923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2025-03-04. Estimated completion is 2026-08-30.
What conditions does trial NCT06890923 study?
This clinical trial studies the following conditions: Non-Active Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT06890923?
The interventions under investigation include: Foralumab TZLS-401 100 µg (DRUG).
Who is sponsoring clinical trial NCT06890923?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06890923 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06890923's enrollment target sits among peer trials
55 1153rd of 2000 higher than 842 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI